Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study.

ABSTRACT:

Background

Uveal melanoma (UM) is the most common intraocular malignancy in adults. In contrast to cutaneous melanoma (CM), there is no standard therapy, and the efficacy and safety of dual checkpoint blockade with nivolumab and ipilimumab is not well defined.

Methods

We conducted a retrospective analysis of patients with metastatic UM (mUM) who received treatment with ipilimumab plus nivolumab across 14 academic medical centers. Toxicity was graded using National Cancer Institute Common Terminology Criteria for Adverse Events V.5.0. Progression-free survival (PFS) and overall survival (OS) were calculated using Kaplan-Meier methodology.

Results

89 eligible patients were identified. 45% had received prior therapy, which included liver directed therapy (29%), immunothe

SUBMITTER: Najjar YG 

PROVIDER: S-EPMC7319717 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature